NASDAQ:ITRM Iterum Therapeutics (ITRM) Stock Price, News & Analysis $1.01 +0.03 (+3.06%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.00 -0.01 (-0.50%) As of 05/30/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Iterum Therapeutics Stock (NASDAQ:ITRM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Iterum Therapeutics alerts:Sign Up Key Stats Today's Range$0.98▼$1.0550-Day Range$0.92▼$1.3952-Week Range$0.81▼$3.02Volume568,461 shsAverage Volume1.04 million shsMarket Capitalization$40.40 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company OverviewIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Read More… Iterum Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreITRM MarketRank™: Iterum Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 737th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingIterum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageIterum Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Iterum Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Iterum Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iterum Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Iterum Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.30% of the float of Iterum Therapeutics has been sold short.Short Interest Ratio / Days to CoverIterum Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Iterum Therapeutics has recently increased by 24.04%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIterum Therapeutics does not currently pay a dividend.Dividend GrowthIterum Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.30% of the float of Iterum Therapeutics has been sold short.Short Interest Ratio / Days to CoverIterum Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Iterum Therapeutics has recently increased by 24.04%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.43 News SentimentIterum Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Iterum Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for ITRM on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Iterum Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Iterum Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of Iterum Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 9.21% of the stock of Iterum Therapeutics is held by institutions.Read more about Iterum Therapeutics' insider trading history. Receive ITRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ITRM Stock News HeadlinesIterum Therapeutics Announces Extension of Term of Promissory NoteMay 19, 2025 | globenewswire.comIterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ...May 14, 2025 | finance.yahoo.com"Elon’s #1 AI Stock” SET TO SOARBecause Elon Musk's AI promises to be 100x more powerful. After all, ChatGPT just works online... While Elon's AI works in the real world.May 31, 2025 | Behind the Markets (Ad)Iterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026May 13, 2025 | msn.comIterum Therapeutics plc (ITRM) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comIterum Therapeutics Reports First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comA Look Ahead: Iterum Therapeutics's Earnings ForecastMay 12, 2025 | benzinga.comIterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025May 6, 2025 | globenewswire.comSee More Headlines ITRM Stock Analysis - Frequently Asked Questions How have ITRM shares performed this year? Iterum Therapeutics' stock was trading at $1.77 on January 1st, 2025. Since then, ITRM shares have decreased by 42.9% and is now trading at $1.01. View the best growth stocks for 2025 here. How were Iterum Therapeutics' earnings last quarter? Iterum Therapeutics plc (NASDAQ:ITRM) announced its earnings results on Tuesday, May, 13th. The company reported ($0.14) earnings per share for the quarter, meeting the consensus estimate of ($0.14). Read the conference call transcript. When did Iterum Therapeutics' stock split? Iterum Therapeutics's stock reverse split on the morning of Thursday, August 18th 2022. The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Iterum Therapeutics IPO? Iterum Therapeutics (ITRM) raised $80 million in an initial public offering (IPO) on Friday, May 25th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. Who are Iterum Therapeutics' major shareholders? Top institutional investors of Iterum Therapeutics include OneDigital Investment Advisors LLC (0.29%). Insiders that own company stock include Michael W Dunne, Corey N Fishman, Brenton Karl Ahrens and Sailaja Puttagunta. View institutional ownership trends. How do I buy shares of Iterum Therapeutics? Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Iterum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Iterum Therapeutics investors own include NVIDIA (NVDA), Onconova Therapeutics (ONTX), Zoom Video Communications (ZM), Tesla (TSLA), Meta Platforms (META), SNDL (SNDL) and Atossa Therapeutics (ATOS). Company Calendar Last Earnings5/13/2025Today5/31/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ITRM CIK1659323 Webwww.iterumtx.com Phone(531) 669-4820FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$9.00 Low Stock Price Target$9.00 Potential Upside/Downside+791.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.77 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-90.85% Debt Debt-to-Equity RatioN/A Current Ratio1.41 Quick Ratio1.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-8.42Miscellaneous Outstanding Shares40,000,000Free Float31,400,000Market Cap$40.40 million OptionableNot Optionable Beta2.91 10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:ITRM) was last updated on 5/31/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.